Preferred Label : Edoxaban Tosylate;

NCIt synonyms : Edoxaban Tosilate; N-(5-Chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N- dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2- carboxamido)cyclohexyl)oxamide, 4- methylbenzenesulfonate;

NCIt definition : The tosylate salt form of edoxaban, an orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion.;

UNII : 32W99UE810;

InChIKey : ZLFZITWZOYXXAW-QXXZOGQOSA-N;

CAS number : 480449-71-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 480449-71-6 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Savaysa;

Molecule name : DU-176b;

Chemical formula : C24H30ClN7O4S.C7H8O3S;

Details


Main resources

You can consult :


https://www.has-sante.fr/portail/jcms/c_2826827/fr/lixiana
2018
false
false
false
France
French
English
treatment outcome
edoxaban
Edoxaban Tosylate
administration, oral
stroke
embolism
adult
risk factors
atrial fibrillation
deep vein thrombosis
deep vein thrombosis
recurrence
pulmonary embolism
pulmonary embolism
hemorrhage
edoxaban
hemorrhage
Factor Xa Inhibitors
edoxaban
evaluation of the transparency committee
venous thrombosis
venous thrombosis
pyridines
thiazoles
pyridines
thiazoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Roteas
2017
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
edoxaban
edoxaban
Edoxaban Tosylate
Edoxaban Tosylate
drug approval
europe
product surveillance, postmarketing
administration, oral
stroke
embolism
adult
risk factors
atrial fibrillation
deep vein thrombosis
deep vein thrombosis
recurrence
pulmonary embolism
pulmonary embolism
drug interactions
pregnancy
breast feeding
hemorrhage
Edoxaban Tosylate
hemorrhage
Factor Xa Inhibitors
Factor Xa Inhibitors
edoxaban
drug evaluation, preclinical
drug evaluation
venous thrombosis
venous thrombosis
pyridines
thiazoles
pyridines
thiazoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Lixiana
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
edoxaban
edoxaban
Edoxaban Tosylate
Edoxaban Tosylate
drug approval
europe
product surveillance, postmarketing
administration, oral
stroke
embolism
adult
risk factors
atrial fibrillation
deep vein thrombosis
deep vein thrombosis
recurrence
pulmonary embolism
pulmonary embolism
drug interactions
pregnancy
breast feeding
hemorrhage
edoxaban
Edoxaban Tosylate
hemorrhage
Factor Xa Inhibitors
Factor Xa Inhibitors
Factor Xa Inhibitors
edoxaban
drug evaluation, preclinical
venous thrombosis
venous thrombosis
pyridines
thiazoles
pyridines
thiazoles
pyridines
thiazoles

---
Nous contacter.
21/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.